EP3727441A1 - Méthodes et appareil pour l'administration de vaccins contre le virus de l'hépatite b (vhb) - Google Patents

Méthodes et appareil pour l'administration de vaccins contre le virus de l'hépatite b (vhb)

Info

Publication number
EP3727441A1
EP3727441A1 EP18830986.8A EP18830986A EP3727441A1 EP 3727441 A1 EP3727441 A1 EP 3727441A1 EP 18830986 A EP18830986 A EP 18830986A EP 3727441 A1 EP3727441 A1 EP 3727441A1
Authority
EP
European Patent Office
Prior art keywords
kit
hbv
cartridge
electrodes
reservoir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18830986.8A
Other languages
German (de)
English (en)
Inventor
Daniel BODEN
Helen Horton
Jean-Marc Edmond Fernand Marie Neefs
Soumitra Roy
Andrew W. Hannaman
Robert M. Bernard
Stephen A. Morse
Oliver Ruck
Adam Hartman
Thomas David COX
Dorien DE POOTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Ichor Medical Systems Inc
Original Assignee
Janssen Sciences Ireland ULC
Ichor Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland ULC, Ichor Medical Systems Inc filed Critical Janssen Sciences Ireland ULC
Publication of EP3727441A1 publication Critical patent/EP3727441A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
    • A61B17/205—Vaccinating by means of needles or other puncturing devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0412—Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0502—Skin piercing electrodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A61N1/303—Constructional details
    • A61N1/306—Arrangements where at least part of the apparatus is introduced into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M2005/2073—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically preventing premature release, e.g. by making use of a safety lock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • FIGS. 25A-25H show the design and optimization of expression cassettes and DNA plasmids encoding HBV pol and core antigens as described in Example 1;
  • FIG. 25A is a schematic representation of an expression strategy in which coding sequences of the HBV core and pol antigens are fused in frame;
  • FIG. 25B is a schematic representation of an expression strategy in which coding sequences of both the core and pol antigens are expressed from a single plasmid by means of the ribosomal FA2 slippage site;
  • FIG. 25C is a schematic representation of an expression strategy in which the core and pol antigens are expressed from two separate plasmids;
  • FIG. 25A is a schematic representation of an expression strategy in which coding sequences of the HBV core and pol antigens are fused in frame;
  • FIG. 25B is a schematic representation of an expression strategy in which coding sequences of both the core and pol antigens are expressed from a single plasmid by means of the
  • the disclosure provides an apparatus for the delivery of an HBV vaccine to a predetermined site within a subject, comprising a cartridge assembly comprising an outer cartridge, an inner cartridge, a reservoir containing the HBV vaccine, wherein a reservoir containment volume is contained within the outer cartridge and configured to receive the reservoir; an applicator comprising a cartridge assembly receiving volume, a needle hub, and an insertion detector, wherein the insertion detector senses loading of the reservoir in the reservoir containment volume; at least one interlock, wherein the interlock facilitates proper execution of the HBV vaccine administration procedure; at least one injection orifice through which the HBV vaccine is administered; a plurality of penetrating electrodes arranged with a predetermined spatial relationship relative to the orifice; an electrical field generator for generating an electrical signal operatively connected to the electrodes; and a controlled source of energy sufficient to transfer a predetermined amount of the HBV vaccine at a predetermined rate from the reservoir through the orifice to the predetermined site within the subject.
  • first nucleic acid molecule and the second nucleic acid molecule are present in the same nucleic acid molecule or in two different nucleic acid molecules.
  • EMTAD This objective is accomplished by controlling the spatial and temporal administration of an HBV vaccine relative to application of electrical signals.
  • EMTAD is initiated by HBV vaccine injection using a conventional needle-syringe. After the agent has been administered, a device suitable for ESA is applied to the subject at a designated location.
  • an HBV core antigen useful for the application is a consensus antigen, preferably a consensus antigen derived from HBV genotypes B, C, and D, more preferably a truncated consensus antigen derived from HBV genotypes B, C, and D.
  • the term“protective immunity” or“protective immune response” means that the vaccinated subject is able to control an infection with the pathogenic agent against which the vaccination was done. Usually, the subject having developed a“protective immune response” develops only mild to moderate clinical symptoms or no symptoms at all. Usually, a subject having a“protective immune response” or“protective immunity” against a certain agent will not die as a result of the infection with said agent.
  • An immunogenically effective amount can vary depending upon a variety of factors, such as the physical condition of the subject, age, weight, health, etc.; the particular application, e.g., providing protective immunity or therapeutic immunity; and the particular disease, e.g., viral infection, for which immunity is desired.
  • An immunogenically effective amount can readily be determined by one of ordinary skill in the art in view of the disclosure.
  • CTAA CTAA
  • ESA ESA-like styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-s.
  • apparatus or kits suitable for CTAA including for instance apparatus comprising at least one of automatic injection devices and jet injectors.
  • the cartridge assembly 100 includes an outer cartridge 102, in some cases termed a housing.
  • the outer cartridge 102 is terminated at a distal end by an outer cartridge cap 106.
  • the outer cartridge 102 includes an inner cartridge containment volume 150, for receiving an inner cartridge 103, which is received and moves in a slidable manner in relationship to the outer cartridge 102.
  • the inner cartridge 103 includes a reservoir containment volume 142 in which the reservoir 101 can be situated.
  • the inner cartridge 103 engages with an inner cartridge cap 104 at a distal end.
  • the inner cartridge cap 104 has a number of functions, including to lock electrodes 122 in place (the inner cartridge 103 itself has seams that the electrodes 122 are placed into) and to provide a bearing surface for a stick shield 134.
  • the inner cartridge cap 104 locks onto the inner cartridge 103.
  • the cartridge assembly 100 is inserted into a cartridge assembly receiving volume 403 within the applicator 400. While various ways can be employed to perform this insertion, one way that has been found particularly useful is by way of a pinion gear assembly 448 engaging racks 154 on the outer cartridge 102.
  • the desired depth electrode deployment and/or agent administration is affirmatively selected by the physician or other medicament administrator and the same transmitted to the applicator 400.
  • the depth can be selected by depth selection buttons 409 (or other equivalent interface such as a toggle switch or sliding switch) and the result displayed on injection depth selection indicators 408 (or, again, other equivalent interface).
  • the available injection depths are conveyed to the user by appropriate labeling of the applicator 400 and/or the cartridge 100. In some embodiments, any labeling regarding the injection depth is located on the cartridge 100 and remains visible to the user following installation in the applicator 400. For example, the available injection depths can be labeled on the upper surface of the alignment guide / splay shield 108.
  • One or more interlocks can be in place which must be deactivated before the insertion mechanism gear drive ring 478 is caused to rotate, rotating retaining posts 488 into the channels.
  • the alignment guide / splay shield 108 by testing for continuity between one or more pads 162 and one or more respective pads 164, it can be determined how far backward or proximal the alignment guide / splay shield 108 has been moved by applied force, and thus if sufficient force exists for proper delivery.
  • the state of the circuit is read by the applicator 400 using sensor contacts 434 (see FIG. 16). If sufficient force is indicated, the force contact interlock is deactivated, allowing the user to operate the device.
  • the injection drive mechanism 456 include appropriate sensor and control features to determine the position of the injection drive plunger 484 at the time the injection stroke was halted due to the detection of a fault condition or other circumstance in which halting the injection stroke is necessary. Preferably this is achieved through monitoring of the revolution count of the motor used to drive the injection drive plunger 484, but other methods for monitoring the position of the injection drive plunger 484 including optical or electrical sensors can be employed.
  • An embodiment of the disclosure involves the use of a planar support structure 124 positioned perpendicularly relative to the elongate orientation of the electrodes.
  • the planar support structure is configured with one or more apertures 192 which correspond to the positions of said electrodes in their specified spatial relationship.
  • the size, shape, and position of the apertures are configured to allow the support structure to slide smoothly along the elongate length of the electrodes within the array while constraining unwanted motion perpendicular to the direction of electrode deployment.
  • the coding sequences of consensus HBV core and pol antigens according to each of the above three expression strategies were cloned into the commercially available expression plasmid pcDNA3.
  • pcDNA3 The coding sequences of consensus HBV core and pol antigens according to each of the above three expression strategies were cloned into the commercially available expression plasmid pcDNA3.
  • l. HEK-293T cells were transfected with the vectors and protein expression was evaluated by Western blot using a HBV core-specific antigen.
  • WPRE Woodchuck HBV post-transcriptional regulatory element
  • intron/exon sequence derived from human apolipoprotein Al precursor GenBank: X01038.1
  • HTLV-l human T-cell leukemia virus type 1
  • LTR long terminal repeat
  • composite sequence of the HTLV-l LTR, synthetic rabbit b-globin intron GenBank: V00882.1
  • splicing enhancer triple composite sequence
  • the device aborts the administration procedure and illuminates the procedure fault indicator.
  • the stimulator display of the device provides further instructions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des méthodes et un appareil permettant d'administrer à un sujet, de manière reproductible, constante et efficace, un vaccin contre le VHB. La présente invention comprend un appareil pour l'administration régulée au sujet du vaccin contre le VHB à travers un orifice, une pluralité d'électrodes pénétrantes agencées selon une relation spatiale prédéfinie par rapport à l'orifice, et un générateur de signaux électriques connecté fonctionnellement aux électrodes.
EP18830986.8A 2017-12-19 2018-12-18 Méthodes et appareil pour l'administration de vaccins contre le virus de l'hépatite b (vhb) Withdrawn EP3727441A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762607430P 2017-12-19 2017-12-19
US2017067269 2017-12-19
PCT/US2018/066157 WO2019126120A1 (fr) 2017-12-19 2018-12-18 Méthodes et appareil pour l'administration de vaccins contre le virus de l'hépatite b (vhb)

Publications (1)

Publication Number Publication Date
EP3727441A1 true EP3727441A1 (fr) 2020-10-28

Family

ID=65009810

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18830986.8A Withdrawn EP3727441A1 (fr) 2017-12-19 2018-12-18 Méthodes et appareil pour l'administration de vaccins contre le virus de l'hépatite b (vhb)

Country Status (12)

Country Link
EP (1) EP3727441A1 (fr)
JP (1) JP2021506431A (fr)
KR (1) KR20200101388A (fr)
CN (1) CN111867624A (fr)
AU (1) AU2018390825A1 (fr)
BR (1) BR112020012171A2 (fr)
CA (1) CA3085492A1 (fr)
IL (1) IL275429A (fr)
MA (1) MA51292A (fr)
MX (1) MX2020006478A (fr)
SG (1) SG11202005709QA (fr)
WO (1) WO2019126120A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
EP3986458A1 (fr) * 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Company Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
CN111267290B (zh) * 2020-02-25 2021-09-21 南京六合科技创业投资发展有限公司 一种管道保温维护用保温料自动搅拌填充设备
WO2023233290A1 (fr) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Agents d'arni ciblant pd-l1

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US5873549A (en) 1996-09-25 1999-02-23 Mcdonnell Douglas Corporation Vehicle rotation and control mechanism
WO2005012502A2 (fr) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Procedes d'identification de variants optimaux d'epitopes peptidiques
SI1729848T1 (sl) * 2004-03-08 2015-08-31 Ichor Medical Systems Inc. Izboljšani aparat za električno posredovan dovod terapevtske snovi
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
CN102851313B (zh) * 2008-01-28 2015-01-28 多贝尔有限公司 一种乙型肝炎疫苗及其制备工艺
KR20120052352A (ko) * 2009-08-07 2012-05-23 트랜스진 에스.에이. Ｈｂｖ 감염을 치료하는 조성물
EA202092990A3 (ru) * 2011-02-11 2021-07-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу
CA2827150C (fr) * 2011-02-12 2018-09-11 Globeimmune, Inc. Therapeutique a base de levure pour infection chronique par l'hepatite b
TWI575070B (zh) * 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
WO2016020538A1 (fr) * 2014-08-08 2016-02-11 Transgene Sa Traitement en association d'un vaccin contre le hbv et d'un anticorps pour traiter des infections à hbv.
CA2962799A1 (fr) * 2014-10-01 2016-04-07 The Trustees Of The University Of Pennsylvania Vaccins possedant un antigene et une interleukine-21 en tant qu'adjuvant
CA3018223A1 (fr) * 2016-03-28 2017-10-05 Ichor Medical Systems, Inc. Procede et appareil permettant d'administrer des agents therapeutiques

Also Published As

Publication number Publication date
JP2021506431A (ja) 2021-02-22
SG11202005709QA (en) 2020-07-29
WO2019126120A1 (fr) 2019-06-27
MX2020006478A (es) 2020-09-22
AU2018390825A1 (en) 2020-06-18
CN111867624A (zh) 2020-10-30
IL275429A (en) 2020-08-31
KR20200101388A (ko) 2020-08-27
MA51292A (fr) 2020-10-28
CA3085492A1 (fr) 2019-06-27
BR112020012171A2 (pt) 2020-11-24

Similar Documents

Publication Publication Date Title
AU2022202299B2 (en) Method and apparatus for delivery of therapeutic agents
EP3727441A1 (fr) Méthodes et appareil pour l'administration de vaccins contre le virus de l'hépatite b (vhb)
US11389531B2 (en) Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
US10252004B2 (en) Method and apparatus for delivery of therapeutic agents
Wallace et al. Tolerability of two sequential electroporation treatments using MedPulser DNA delivery system (DDS) in healthy adults
TW201938214A (zh) 用於遞送b型肝炎病毒(hbv)疫苗之方法及裝置
EA043519B1 (ru) Способ и устройство для доставки вакцин против вируса гепатита b (hbv)
Hannaman Electroporation based TriGrid™ delivery system (TDS) for DNA vaccine administration
JPWO2021044776A1 (ja) 自動注射装置

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200626

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HORTON, HELEN

Inventor name: MORSE, STEPHEN, A.

Inventor name: NEEFS, JEAN-MARC EDMOND FERNAND MARIE

Inventor name: BODEN, DANIEL

Inventor name: RUCK, OLIVER

Inventor name: BERNARD, ROBERT, M.

Inventor name: DE POOTER, DORIEN

Inventor name: HARTMAN, ADAM

Inventor name: COX, THOMAS, DAVID

Inventor name: ROY, SOUMITRA

Inventor name: HANNAMAN, ANDREW, W.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40039938

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230515

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230926